News
Biotech cools off in August as capital markets weaken September 01, 2010 | Press Release
Biotech gets hot in July August 02, 2010 | Press Release
Shawn Cross appointed CEO of Burrill Merchant Banking Group July 28, 2010 | Press Release
See all NewsInternational
BGC focuses on merchant banking and investing opportunities in Greater China. We can assist your company in meeting its corporate objectives if you are:
A North America or Europe based company
- Interested in outsourcing to Greater China
- Interested in entering the Chinese market
- Seeking strategic partnerships with Chinese companies
- Seeking cross-border M&A opportunities
A Chinese company
- Seeking to in-license overseas products or technologies
- Interested in forming a strategic alliance with overseas companies
- Seeking cross-border M&A opportunities
- Interested in entering the overseas markets
| Top Challenges Faced by Biopharmaceutical Companies | How China Strategies can Provide the Solution |
| High drug development cost >$1 billion for each successfully developed drug |
Outsource to China Pre-clinical drug development ~20% U.S. cost |
| High attrition rate in new drug development <1% success rate from preclinical to NDA approval |
Accelerated first in man POC in China More “shots on goal” with early elimination of unacceptable drug candidates |
| Fierce market competition Need to capture value for drugs outside U.S. and Europe |
Technology transfer to China Capture large market of unmet needs |
| Need top line growth Increasing cost of drug development and pressure from healthcare provider to lower price | China expansion China pharmaceutical market to become top 5 by 2010 |
